Abstract
To the Editor:— Many glowing reports of the early beneficial effects of the isonicotinic acid hydrazides (rimifon, nydrazid, and marsilid) in patients with tuberculosis have appeared in newspapers and magazines as well as in the medical journals. Little has been mentioned, however, about the emergence of drug resistant tubercle bacilli in the sputum of patients treated with these drugs. Since one of the major drawbacks to the use of streptomycin alone in pulmonary tuberculosis proved to be the rapid emergence of streptomycin resistant strains of tubercle bacilli, and this regardless of the dosage, it is important to determine as soon as possible whether the same situation will arise during therapy with the isonicotinic acid hydrazides. Six patients began to receive isonicotinic acid hydrazide (rimifon) or its isopropyl derivative (marsilid) on Jan. 18, 1952. All had chronic cavitary pulmonary tuberculosis that had not responded satisfactorily to previous treatment, including streptomycin and
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
